title: CML: new biologic therapies, endpoints and questions.
authors.forename: A
authors.initials: A
authors.lastname: Martin
authors.forename: B D
authors.initials: BD
authors.lastname: Cheson
mesh_terms: D003131:Combined Modality Therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D011994:Recombinant Proteins; D012074:Remission Induction
chemical_list: D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007371:Interferon-gamma